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Abstract
Background: The ability to respond to anti-growth signals is critical to maintain tissue homeostasis and loss of this negative
growth control safeguard is considered a hallmark of cancer. Negative growth regulation generally occurs during the G0/G1
phase of the cell cycle, yet the redundancy and complexity among components of this regulatory network has made it
difficult to discern how negative growth cues protect cells from aberrant proliferation.
Methodology/Principal Findings: The retinoblastoma protein (pRB) acts as the final barrier to prevent cells from entering
into the cell cycle. By introducing subtle changes in the endogenous mouse Rb1 gene (Rb1
DL), we have previously shown
that interactions at the LXCXE binding cleft are necessary for the proper response to anti-growth signals such as DNA
damage and TGF-b, with minimal effects on overall development. This disrupts the balance of pro- and anti-growth signals
in mammary epithelium of Rb1
DL/DL mice. Here we show that Rb1
DL/DL mice are more prone to mammary tumors in the Wap-
p53
R172H transgenic background indicating that negative growth regulation is important for tumor suppression in these
mice. In contrast, the same defect in anti-growth control has no impact on Neu-induced mammary tumorigenesis.
Conclusions/Significance: Our work demonstrates that negative growth control by pRB acts as a crucial barrier against
oncogenic transformation. Strikingly, our data also reveals that this tumor suppressive effect is context-dependent.
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Introduction
Maintenance of tissue homeostasis is a tightly regulated process
and the loss of responsiveness to negative growth signals can alter
this delicate balance, leading to cancer [1]. This is especially
evident in the breast, where epithelial cells undergo cycles of
quiescence, proliferation, differentiation, and apoptosis during the
menstrual cycle and as a result of pregnancy [2]. Tight negative
growth control of the mammary epithelial compartment is crucial,
and disruption of the balance between mitogenic and anti-growth
signals can leave this tissue susceptible to the formation of cancer
[3,4]. Therefore, delineating how negative growth control of
breast epithelial cells is lost during tumor formation is essential to
understand the pathogenesis of breast cancer.
Insensitivity to negative growth signals is considered a hallmark
of cancer cells [1]. This means that the mechanism that conveys
growth inhibiting signals from DNA damage or transforming
growth factor b (TGF-b) to the cell cycle machinery is universally
disrupted. In general, growth inhibiting signals arrest the cell cycle
by blocking cyclin dependent kinase (CDK) activity through the
actions of cyclin dependent kinase inhibitors (CKIs) such as
p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 [3,5]. This in turn
activates the retinoblastoma protein (pRB). In cell culture,
disruption of an individual CKI, such as p21Cip1, can result in
deregulated proliferation despite signals from negative growth
regulatory stimuli such as DNA damage [6,7]. However, negative
growth regulators such as TGF-b are capable of inducing a cell
cycle arrest in the absence of any one of these CKI proteins
[8,9,10,11]. Furthermore, ablation of individual CKI genes in
mice has no effect on viability and is accompanied by surprisingly
few developmental abnormalities. Interestingly, each knockout
mouse strain develops tumors in a specific subset of tissues, but
none of these mice develop mammary tumors [11,12,13,14,
15,16,17,18]. In fact, pRB itself was previously considered
dispensable for mammary development [19]. This is surprising
because pRB pathway components such as cyclin D1 are
commonly amplified, and pRB itself is sometimes lost in human
breast cancers and these are direct targets of CKI regulation
[20,21,22,23,24]. Thus, even though the current body of literature
suggests that anti-growth effects greatly influence mammary
epithelial cells [1], mouse models reveal layers of complexity that
make it challenging to understand how negative growth responses
protect mammary epithelial cells from aberrant proliferation and
ultimately tumorigenesis.
Activation of pRB maintains cells in G0/G1 and prevents
inappropriate cell cycle entry [3]. Breast epithelial cells frequently
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growth factors like TGF-b, and other cellular stresses. All of these
serve to activate pRB and arrest proliferation [25]. Using a knock-
in mouse model with a discrete defect in the pocket domain of Rb1
(Rb1
DL), we have reported the remarkable discovery that pRB uses
interactions with LXCXE-motif-containing proteins almost exclu-
sively for growth arrest in response to stressful negative growth
stimuli, and this mechanism is largely dispensable for cell cycle
control in development allowing us to obtain viable animals with
this defect [26,27]. The lone circumstance in development where
pRB interactions with LXCXE containing proteins, such as
histone deacetylases, are critical is in mammary epithelium. In this
tissue, ductal morphology and branching are normal, but there is
mild hyperplasia of the luminal cell compartment [26]. Our data
indicates that, the Rb1
DL mutation results in an inability to silence
transcription of E2F target genes and renders cells insensitive to
anti-growth signals, including TGF-b, DNA damage, and other
senescence cues [26,27]. Furthermore, cells from these mice fail to
induce growth arrest in response to ectopic expression of the CKI
proteins p16Ink4a and p21Cip1 [26]. This suggests that there are
likely many stress-induced negative growth signals to which cells
from these mice are uniquely resistant. Since pRB-dependent
negative growth control is dramatically reduced in the mammary
glands of Rb1
DL mice, but viability and overall development are
normal, these animals provide a unique opportunity to examine
the impact of negative growth signals in suppressing mammary
cancer.
In order to understand the role of pRB LXCXE-dependent
negative growth control during mammary tumorigenesis, we have
crossed our mice with a Wap-p53
R172H transgenic strain. Wap-
p53
R172H; Rb1
DL/DL females developed mammary tumors more
frequently and at a significantly younger age than control mice,
while showing no differences in histopathological characteristics or
metastasis. This strongly suggests that loss of negative growth
regulation in this model exacerbates cancer development at a very
early stage. In contrast, co-expression of Neu and Rb1
DL did not
accelerate mammary tumor initiation, progression, or metastatic
dissemination. Surprisingly, the contrasting data between the two
transgenic mammary tumor models indicates that failure to
respond to negative growth signals by pRB affects cancer
incidence in a context-dependent manner.
Results
pRB-LXCXE interactions act as an initial barrier to tumor
formation
Our lab has previously generated a knock-in mouse model
(Rb1
DL) to disrupt the LXCXE binding cleft on the retinoblastoma
tumor suppressor protein [28]. Loss of LXCXE-dependent
interactions, between pRB and enzymes such as histone
deacetylases, disrupts negative growth control in the mammary
gland during development. This leads to hyperplasia of the ductal
epithelium that is ubiquitously detectable in virgin animals
between four and 16 weeks of age [26]. The Rb1
DL mutation
alone does not lead to spontaneous mammary cancer, perhaps
because this mutation doesn’t increase the cellular proliferation
rate, but alters the response to negative growth cues [26,29]. Since
hyperplasia of ductal epithelia is considered a risk factor for
human breast cancer [30,31], we postulated that the Rb1
DL
mutation would exacerbate cancer pathogenesis when combined
with other oncogenic changes that provide a proliferative signal.
To explore this possibility, we first performed a soft agar colony
assay using Rb1
+/+ and Rb1
DL/DL mouse embryonic fibroblasts
(MEFs) expressing a dominant negative form of p53 and an
oncogenic allele of Ras (pLXSN dn p53/Ras
V12) [32]. Expression
of these oncogenes resulted in a greater frequency of colonies in
Rb1
DL/DL MEFs compared with controls (Fig. 1a, b). Furthermore,
many Rb1
DL/DL colonies were also larger than control colonies
(Fig. 1a), suggesting that cells lacking pRB-LXCXE interactions
were able to transform earlier. Since the effect of the Rb1
DL
mutation is exerted after only a few cell divisions, we interpret this
phenotype to be caused by a defect in negative growth control
rather than genome instability, which can also result from
expression of the Rb1
DL allele [28,29]. This provided proof of
principle that pRB-LXCXE-dependent anti-growth effects can
protect cells from oncogenic transformation.
To validate that pRB-LXCXE interactions can exert a tumor
suppressive effect in the mammary gland, we crossed our mice into
the Wap-p53
R172H background. Wap-p53
R172H is a dominant
negative form of p53 driven by the whey acidic protein promoter,
which is expressed in the mammary gland during pregnancy and
lactation. We bred cohorts of Wap-p53
R172H; Rb1
+/+ and Wap-
p53
R172H; Rb1
DL/DL females through five rounds of pregnancy in
order to induce transgene expression (Fig. 2a). Since Rb1
DL/DL
females are frequently unable to nurse their pups [26], all live pups
were removed two days after birth to ensure consistent timing of
Figure 1. The Rb1
DL mutation confers sensitivity to oncogenic
transformation. A) MEF cells corresponding to the indicated
genotypes were transduced with retroviruses expressing dominant
negative (dn) p53 and Ras
V12 and plated in soft agar to allow colonies to
form. Photomicrographs were taken after a two-week growth period.
Number in the bottom right corner of each photomicrographs indicate
the number of colonies that contained 5 or more cells. Scale: 200 mm. B)
The percentage of wild type and mutant cells that transformed and
grew into a colony was calculated from five randomly photographed
microscopic images. A cell was counted as transformed if it formed a
colony whose size appeared to be at least 5 cells. * indicates a
statistically significant difference (Student’s t test; P,0.005). Error bars
indicate one standard deviation from the mean for at least three
replicates.
doi:10.1371/journal.pone.0016434.g001
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R172H expression
leads to genomic instability [33,34], so we reasoned that
expression of p53
R172H during pregnancy and lactation would
create random mutations. We expected that some of these
mutations would drive tumorigenesis later, after the transgene
was turned off, and this would allow us to assess how a diminished
response to negative growth regulators affects mammary tumor-
igenesis. Both Wap-p53
R172H; Rb1
+/+ and Wap-p53
R172H; Rb1
DL/DL
females developed high grade mammary adenocarcinomas,
characterized by high cytological variability. Many cells exhibited
large cellular and nuclear size which is comparable to other studies
using Wap-p53
R172H mice, indicating that the transgene was active
Figure 2. pRB-LXCXE interactions protect against tumor formation caused by the Wap-p53
R172H transgene. A) Experimental outline for
the Wap-p53
R172H tumor study. Mice were bred through five rounds of pregnancy (thin arrows) to transiently induce p53
R172H expression within the
mammary gland. After the fifth pregnancy, males were removed and females were palpated weekly to monitor tumor formation. Median tumor-free
survival for each genotype is marked with the colored arrows. B) Representative H&E stained paraffin sections from tumors harvested from Wap-
p53
R172H; Rb1
+/+ and Wap-p53
R172H; Rb1
DL/DL mice. Arrows indicate mitotic figures that are shown in the inset. Scale: 50 mm. C) The mitotic index for
Wap-p53
R172H; Rb1
+/+ and Wap-p53
R172H; Rb1
DL/DL mice is indicated, along with the average mitotic index for each genotype. Values were derived by
quantifying the number of mitotic figures in five random fields of view for each mouse. D) Kaplan-Meier graph of mammary tumorigenesis is shown
for Wap-p53
R172H; Rb1
+/+ and Wap-p53
R172H; Rb1
DL/DL females (log rank test; P=0.0238). Values in brackets indicate the number of mice that developed
tumors. E) Carmine Red–stained mammary whole mounts from tumor-free glands in mice that had mammary tumors are shown for both genotypes
in the Wap-p53
R172H background. Arrows indicate hyperplastic nodules and LN indicates lymph nodes. Scale: 2 mm. The number of hyperplastic
nodules in each whole mount section was also quantified for each genotype along with the average number of hyperplastic nodules.
doi:10.1371/journal.pone.0016434.g002
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both genotypes displayed high but comparable rates of mitosis and
similar rates of tumor growth (Fig. 2c and data not shown),
demonstrating that the rate of proliferation was similar for Wap-
p53
R172H; Rb1
+/+ and Wap-p53
R172H; Rb1
DL/DL tumors.
While mice from both genotypes developed similar types of
tumors,we foundanincreased frequencyoftumorformationinWap-
p53
R172H; Rb1
DL/DL females. 63.6% of Wap-p53
R172H; Rb1
DL/DL
females compared to 44.4% of Wap-p53
R172H; Rb1
+/+ females
developed tumors over the course of the study. Importantly, loss of
pRB-LXCXE interactions in the Wap-p53
R172H background also
resulted in earlier tumor onset as detected by mammary palpation
(Fig. 2d) (Log rank test, P=0.0238). Like the data from our soft agar
colony assay, this suggests that pRB-dependent anti-growth control
can act as a barrier to tumor initiation, and when it is lost in Rb1
DL/DL
females Wap-p53
R172H c a nt h e nd r i v et u m o u rp r o g r e s s i o n .T o
explore this concept further, we examined tumor-free mammary
glands from our tumor-burdened mice. Some mammary glands had
extensive lobuloalveolar development, preventing an assessment of
abnormal proliferation by whole mount staining. However, we
examined glands where tumors were not palpable among the
remaining necropsied animals, and discovered that there was a small
increase in the number of hyperplastic lesions in the Wap-p53
R172H;
Rb1
DL/DL mice (Fig. 2e). Together with the increased frequency of
tumors and shortened timing of tumor onset in Wap-p53
R172H;
Rb1
DL/DL females, these data indicate that pRB-dependent anti-
growth control acts as an initial barrier to tumor formation in the
mammary gland. In addition, both Wap-p53
R172H; Rb1
+/+ and Wap-
p53
R172H; Rb1
DL/DL tumors were able to metastasize to the lungs, and
there were no major differences in the appearance of the metastases,
or the number, or size of these metastases (Fig. 3). This is distinct from
previous reports demonstrating that loss of pRB-mediated genomic
stability leads to more aggressive tumors and increased metastasis
[29]. Because the frequency of cancer incidence and age of onset are
exacerbated by the Rb1
DL mutation, but aspects of progression such
as proliferation rate and metastasis are indistinguishable from
controls, we conclude that reduced responsiveness to negative growth
signals likely functions as a barrier to tumor initiation at a very early
stage in cancer pathogenesis.
Retinoblastoma-dependent negative growth effects on
tumorigenesis are context-dependent
The advantage of the Wap-p53
R172H model is that it introduces
random mutations and this creates a selection for ones that can
cooperate with defects found in Rb1
DL/DL mice. However, this also
prevents us from knowing what the initiating oncogenic mutations
were and how they normally engage negative growth responses
that activate a pRB-LXCXE-dependent arrest. For this reason we
also used a transgenic line that expresses a dominantly acting
oncogene so that the origin of oncogenesis would be known. To
determine how pRB-dependent responses to negative growth
signals affect mammary tumorigenesis in this context, we crossed
our mice into the Tg(MMTVneu)202Mul (herein referred to as Neu)
background, where expression of the rat proto-oncogene Neu is
driven by the MMTV promoter. These mice normally develop
focal mammary tumors with a high rate of metastasis to the lung
[35]. We chose this transgenic line because Neu is known to
activate the Ras pathway [36] and our data in Figure 1 indicates
that pRB-dependent growth arrest opposes it. Furthermore,
expression of activated Neu in mice with disrupted TGF-b
signaling results in reduced tumor latency [37]. Conversely, when
crossed to mice that overexpress TGF-b or a constitutively active
TGF-b receptor, primary tumor formation is delayed or tumor
growth is slowed [37,38]. This anti-tumor effect is commonly
attributed to TGF-b-induced cell cycle arrest, although this aspect
of its signaling has not been testable in isolation before now. For
these reasons Neu mice offer a relatively well characterized system
in which to determine how important negative growth signalling is
in opposing mammary cancer formation.
Since TGF-b is a key negative regulator of proliferation in the
mammary epithelial compartment and induces a G1 arrest in a
pRB-LXCXE-dependent manner [26], we next wanted to
characterize the Neu; Rb1
DL/DL genotype to ensure that this
experimental system would allow us to address the role of negative
growth responses during tumorigenesis as we expected. To this
end we tested Rb1
+/+, Rb1
DL/DL, and Rb1
DL/+ mammary epithelial
cells (MECs) for their ability to respond to TGF-b–induced G1
arrest (Fig. 4a). This confirmed our previous results that TGF-b’s
cytostatic response is vastly diminished in Rb1
DL/DL cells [26].
Surprisingly, Rb1
DL/+ MECs have a similar defect in TGF-b
growth control indicating that mutation of only one copy of Rb1 is
sufficient to abrogate its arrest mechanism. Consistent with this
observation, examination of mammary epithelia in Rb1
DL/+ virgin
female mice revealed they have a similar degree of hyperplasia as
we have previously reported for Rb1
DL/DL mice (Fig. 4b) [26]. The
proto-oncogenic Neu in these young mice needs to be activated by
a deletion in its extracellular domain, so the growth signals that
will drive cancer formation are not evident at this early stage [39].
Figure 3. Metastases form in the Wap-p53
R172H; Rb1
+/+ and Wap-
p53
R172H; Rb1
DL/DL mice. A) Representative H&E stained paraffin
sections of lungs harvested from tumor-burdened mice of each
genotype. M denotes metastasis, and L denotes neighboring lung
tissue. Scale: 100 mm. B) The surface area (SA) occupied by lung
metastases relative to the total lung area in tissue sections was
quantified for mice from each genotype along with the average SA.
Values in brackets indicate the number of mice that developed
metastases and { indicates a female that developed metastases to both
the lung and spleen.
doi:10.1371/journal.pone.0016434.g003
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by the Rb1
DL mutation, these mice create an ideal opportunity to
assess how an oncogenic growth signal is opposed. Importantly,
this can be determined by comparing Neu transgenic mice with
wild type Rb1 to either Rb1
DL/+ or Rb1
DL/DL animals.
To assess the importance of pRB-dependent negative growth
control in suppression of primary tumor formation and growth, we
followed cohorts of Neu; Rb1
+/+, Neu; Rb1
DL/+ and Neu; Rb1
DL/DL
females throughout their natural lives and palpated them weekly to
determine the onset of mammary tumor formation. Unfortunately,
the long latency before tumor formation resulted in excessive
grooming in many of our mice and the need to euthanize them
before palpable tumors formed. This was particularly true of the
Neu; Rb1
DL/DL mice. However, the Neu; Rb1
DL/+ animals have a
similar response to TGF-b, indicating that they offer the same
insight into how negative growth signals impact tumorigenesis in
this transgenic model. In contrast to the Wap-p53
R172H; Rb1
DL/DL
mice, there was no difference in tumor latency between the
remaining Neu; Rb1
DL/DL females and females from the other two
genotypes (Fig. 5a). The frequency of tumorigenesis in the Rb1
mutant genotypes was also relatively unchanged from wild type
(85.7% for Rb1
DL/DL and 77.4% for Rb1
DL/+ vs. 90% for wild
type).
This result suggests that negative growth regulatory signals
that depend on pRB do not significantly influence cancer
pathogenesis in Neu transgenic mice. Because this was unexpect-
ed, we also investigated other tumor characteristics to determine
if the Rb1 mutant genotypes altered the tumor type of these mice
in such a way that the direct comparison in Fig. 5a is misleading.
To this end, we classified the tumors histologically and
discovered that they all fit the characteristics of solid or acinar
carcinomas that have been reported previously for Neu mice,
indicating that transgene function was not altered in the different
genotypes (Fig. 5b) [40]. Our expectation from the Wap-p53
R172H
cross is that negative growth responses are most important at the
initiation step. However, Muraoka et al. found that overexpres-
sion of TGF-b did not affect tumor latency of Neu mice, but
instead reduced tumor proliferation [38]. For this reason we
measured the number of mitotic figures in five randomly selected
microscopic fields for each tumor as a means to compare
proliferation and this revealed no significant differences (Fig. 5c).
Furthermore, there were no significant differences in the final
tumor volume (Fig. 5c). Lastly we investigated unaffected
mammary glands from tumor-burdened animals for evidence of
non-malignant nodules by whole mount preparations. Again,
there were no statistically significant differences between the
three Rb1 genotypes and if anything there was a trend toward
fewer nodules in mice bearing the Rb1
DL mutation (Fig. 5d).
These findings are in stark contrast to those for the Wap-p53
R172H
cross, where there was an earlier tumor onset in Wap-p53
R172H;
Rb1
DL/DL females and slightly more hyperplastic nodules (Fig. 2a,
2d, 2e). Together, these data indicate that loss of pRB-dependent
anti-growth control exacerbates Wap-p53
R172H–dependent tu-
mor formation, but leaves Neu-driven tumorigenesis unaltered.
This indicates that during cancer formation, the response to anti-
growth signals by pRB is context-dependent.
In an effort to better relate the combination of the Wap-
p53
R172H and Neu transgenes with our Rb1 mutant, we also
investigated metastasis in Neu; Rb1
+/+, Neu; Rb1
DL/+, and Neu;
Rb1
DL/DL female mice. This revealed that the number of lung
surface metastases that formed during the 60 day period from
initial palpation to euthanasia were similar (Fig. 6a). Furthermore,
these metastatic lesions occupied a similar proportion of tissue
volume when quantified microscopically in lung sections (Fig. 6b).
Lastly, there were no apparent differences in histology between
metastases from the respective genotypes (Fig. 6c). From these
experiments it is clear that the Rb1
DL allele does not enhance the
metastatic potential of mammary tumors whether they form in the
Neu or Wap-p53
R172H backgrounds.
This reveals that pRB can confer responsiveness to negative
growth signals that limit p53
R172H tumorigenic effects. Surpris-
ingly, this aspect of pRB function does not affect Neu-driven
oncogenesis. Unexpectedly, these experiments reveal that loss of
pRB-dependent negative growth responsiveness does not ubiqui-
tously contribute to cancer formation in the mammary gland.
Discussion
Using two transgenic mouse models of breast cancer, we have
examined the importance of pRB-LXCXE interactions during
cancer formation and progression. Our work has revealed that
LXCXE-dependent anti-growth control can act as a barrier to
oncogenic transformation in the mammary gland. Surprisingly,
the Rb1
DL mutation exacerbated Wap-p53
R172H-induced tumor
Figure 4. Defective TGF-b proliferative control in Rb1
DL/DL and
Rb1
DL/+ mice. A) Rb1
+/+, Rb1
DL/+, and Rb1
DL/DL mammary epithelial cells
were treated with TGF-b1 and pulse labeled with BrdU 24 hrs later. The
percentage of cells incorporating BrdU was measured by immunoflu-
orescence microscopy. The fold decrease in proliferation between
treated and untreated parallel cultures was determined and the average
of three independent experiments is shown. * indicates a statistically
significant difference (Student’s t test; P,0.05). Error bars indicate one
standard deviation from the mean. B) H&E staining of paraffin sections
of Rb1
+/+, Rb1
DL/+, and Rb1
DL/DL mammary tissue from 8 week old mice.
Each image displays a representative cross section of ducts. The table
below displays the proportion of hyperplastic (hp) ducts found in
Rb1
+/+, Rb1
DL/+, and Rb1
DL/DL mammary glands. Proportions were
compared between genotypes using a chi-square test. Scale: 100 mm.
{ denotes previously published data that has been provided for
comparison purposes.
doi:10.1371/journal.pone.0016434.g004
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background.
The retinoblastoma protein has several important roles in the cell
including induction of a cell cycle arrest in response to various
stresses, as well as maintaining genome stability [26,27,29]. While it
is possible that the enhanced tumor phenotype observed here is the
result of increased genomic instability, we do not consider this a
likely possibility for several reasons. Recent work demonstrated that
lossof pRB-mediated genome integrity manifests as more aggressive
tumors characterized by altered histopathology compared to
controls [29]. Furthermore, they also exhibited increased metastasis
[29]. In contrast, we saw no change in tumor size, proliferation, or
metastasis in Wap-p53
R172H; Rb1
DL/DL mice. The increase in tumor
penetrance and earlier onset in the Wap-p53
R172H; Rb1
DL/DL
background are more consistent with an inability to induce a
growth arrest. We posit that pRB acts as a braking mechanism,
protecting the cell from aberrant growth in response to stresses in
this transgenic model. Mutations to the LXCXE binding cleft
disrupt this braking system, leaving cells vulnerable to oncogenic
stimuli, such as those generated in the Wap-p53
R172H model.
Figure 5. Loss of pRB-LXCXE interactions does not affect Neu-driven tumorigenesis. A) Onset of mammary tumorigenesis is shown for the
indicated genotypes (log rank test; P=0.6788). Values in brackets indicate the number of mice that developed tumors. B) Representative H&E stained
paraffin sections from tumors harvested from Neu; Rb1
+/+, Neu; Rb1
DL/+, and Neu; Rb1
DL/DL mice 60 days after initial tumor palpation. Arrows indicate
mitotic figures that are shown in the inset. Scale: 50 mm. C) The mitotic index and final tumor volumes for Neu; Rb1
+/+, Neu; Rb1
DL/+, and Neu; Rb1
DL/DL
mice are indicated, along with the average values for each genotype. Mitotic indices were derived by quantifying the number of mitotic figures in five
random fields of view for each mouse. Final tumor volume was calculated using the formula V=0.526W
26L. D) Carmine Red–stained mammary
whole mounts from tumor-free glands in mice that had mammary tumors are shown for the given genotypes. Arrows indicate hyperplastic nodules
and LN indicates lymph nodes. Scale: 2 mm. The number of hyperplastic nodules in each whole mount section was also quantified for each genotype
along with the average number of hyperplastic nodules.
doi:10.1371/journal.pone.0016434.g005
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that protects against Wap-p53
R172H driven tumors is unclear since
mutant p53 acts as a generator of mutations that drive
tumorigenesis almost a year after the transgene has been silenced.
However, the exact source of anti-growth signals that fail to be
received in Wap-p53
R172H; Rb1
DL/DL mice is not the key question;
rather, the Rb1
DL mutation allows us to determine the circum-
stances when the response to negative growth signals are most
important. We interpret our data to indicate that pRB responds to
these signals to oppose oncogenic transformation in mammary
epithelial cells at an early stage in tumorigenesis, before tumors
become palpable. Several lines of evidence support this conclusion.
First, prior analysis of Rb1
DL/DL fibroblasts demonstrates that cell
size and length of G1 and S phases are similar to wild type cells,
indicating that this Rb1 mutant is phenotypically distinct from the
increased rate of proliferation found in Rb1
2/2 cells [28]. Instead,
Rb1
DL/DL cells have a defect in inducing cell cycle arrest in
response to anti-growth signals (Fig. 4a) [26,27]. Second, in both
the Wap-p53
R172H and Neu crosses, the rates of proliferation were
comparable between control tumors and those lacking pRB-
LXCXE interactions (Fig. 2c and Fig. 5c). In contrast, the median
age of tumor onset was significantly lower for Wap-p53
R172H;
Rb1
DL/DL females, compared to control mice (Fig. 2a, 2d).
Similarly, only Wap-p53
R172H; Rb1
DL/DL tumor-free mammary
glands displayed an increase in hyperplastic nodule formation.
This suggests that the Rb1
DL/DL mutation impacts tumorigenesis at
an early stage, rather than increasing proliferation in existing
tumors. Taken together, we interpret these findings to indicate
that pRB responds to anti-growth signals to act as a barrier to
initial tumor formation by inducing cell cycle arrest; loss of this
anti-growth pathway leaves mammary epithelial cells vulnerable to
oncogenic transformation caused by p53
R172H.
Unresponsiveness to negative growth signals is described as a
hallmark of cancer, implying a ubiquitous need for it to be
eliminated during tumorigenesis [1]. There is little evidence of
how these signals are generated and when they act to block
aberrant proliferation. The evidence of their importance is largely
implied by the frequency of their loss in cell cultures generated
from tumors. Our genetic approach is a first step to gaining better
insight into this mechanism. Our data from studying Neu-induced
tumorigenesis implies that negative growth signals may be lost with
no apparent effect on cancer incidence. However, comparing the
two tumor models used here may be instructive in narrowing
down the possibilities. Both Wap-p53
R172H and Neu (line 202)
require accompanying or sporadic mutations in the transgene to
initiate cancer [34,39]. The Neu transgene requires the deletion of
a small portion of the ectodomain to be become activate and drive
cancer formation. This mechanism has been shown to be
consistent between individual Neu tumors as similar deletions are
generated each time. The resulting activated Neu receptors have
relatively weak transforming activity in comparison with the
original V664E mutant allele [39]. For this reason the relative
strength of the oncogenic signal may be an important factor. This
is consistent with mammary tumors in Wap-p53
R172H; Rb1
DL/DL
mice having incomplete penetrance; some animals may not
acquire sufficiently strong mutations. In addition, mitogenic
signals are known to elicit a negative growth response from
TGF-b in mammary epithelium [41]. For these reasons the
strength of oncogenic growth signal is likely an important cue in
determining if a negative growth arrest mechanism will need to be
overcome during tumor formation. Future experiments will need
to be designed to address this possibility.
Understanding the context in which the response to negative
growth signals is a key tumor suppressor mechanism is a
challenging new question. However, determining what factors
influence context in vivo will greatly influence our understanding of
negative growth control in cancer, and will undoubtedly impact
the classification and treatment of this disease in the future.
Materials and Methods
Mouse strains
The Rb1
DL mouse strain has been described previously [28].
Analyses of Rb1
DL/DL mice were performed on a mixed 129/B6
background. Wap-p53
R172H mice were obtained from the Mouse
Models of Human Cancer Consortium on an FVB background.
These mice express the p53
R172H mutation driven by the whey
Figure 6. Loss of pRB-LXCXE interactions does not affect
metastatic potential in Neu mice. A) The number of lung surface
metastases (LSM) was quantified for individual mice and plotted along
with the average number of LSM per genotype. { indicates lungs with
.59 LSM and { indicates a lung where each of the two metastases
encompassed an entire lobe. B) The SA occupied by lung metastases
relative to the total lung area in tissue sections was quantified for mice
from each genotype along with the average SA for each genotype. C)
Representative H&E stained paraffin sections of lungs from tumor-
burdened mice are shown for each genotype. Scale: 100 mm.
doi:10.1371/journal.pone.0016434.g006
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DL
mutation, creating a mixed 129/B6/FVB genetic background.
Wap-p53
R172H; Rb1
+/+ and Wap- p53
R172H; Rb1
DL/DL females were
bred through five or six rounds of pregnancy to induce expression
of p53
R172H. Live pups were removed at P2 to allow equivalent
timing of transgene expression between genotypes. Tg
(MMTVneu)202Mul (herein called Neu) mice express the wild type
form of the rat Neu oncogene driven by the murine mammary tumor
virus promoter (MMTV) [35]. These mice were obtained from
Jackson Labs on an FVB background and were bred to the Rb1
DL
mutation, creating a mixed 129/B6/FVB genetic background.
Genotyping methods and PCR primers were provided by the
suppliers, or are as outlined by Isaac, et al. [28]. All animals were
housed and handled as approved by the UWO animal use
subcommittee (protocol 2007-058) and CCAC guidelines.
Histology and mammary whole mounts
Full necropsies were performed on tumor-bearing animals after
60 days or at the time of euthanasia. Mammary tumors, lung
tissues, and any other tissues that appeared abnormal were fixed in
formalin and sectioned as previously described [26]. The mitotic
indices were manually counted in 5 high-power fields of view
(4006) for mammary tumors from each genotype. Lung
metastases were identified by gross morphological analysis (surface
metastases) and microscopic analysis (micrometastases). Percent
metastatic surface area (SA) was calculated by measuring the total
two dimensional area occupied by lung metastases in five
hematoxylin and eosin (H&E) stained lung sections, divided by
the total area of the lung in these sections using Volocity 4 software
(Perkin Elmer, Waltham, MA). Analysis of hyperplasia in H&E
stained sections of Rb1
DL/+ mammary glands, as well as Neu
expressing mammary glands, was as described before [26]. For
whole-mount analysis, unaffected mammary glands from tumor-
burdened mice were removed, mounted on glass slides, and
stained with Carmine Red using standard techniques.
Primary cell culture assays
Mammary epithelial cells were harvested and cultured as
previously described [26,42]. Cell culture experiments were
carried out on passage 1 or 2 MECs. TGF-b1 growth inhibition
assays were performed as previously described [26].
Soft Agar Colony Formation Assay
Rb1
+/+ and Rb1
DL/DL MEFs were retrovirally transfected with
the pLXSN dominant negative (dn) p53/Ras
V12 virus as
previously described [32,43]. Infected cells were then grown in
soft agar according to standard protocols [44]. Cells were allowed
to grow for 2 weeks, at which time colonies were photographed
and counted. The cut-off for scoring a colony as transformed was
that its size needed to correspond with the volume of at least 5 cells
(as judged by neighboring single cells). In this way we were
confident that these colonies represented multiple cell divisions.
Acknowledgments
The authors would like to thank numerous colleagues for advice during the
course of this research. We are grateful to lab members who helped with
tumor measurements and the CHRI histology facility for technical
assistance. The pLXSN dn p53/Ras
V12 construct was provided by Piotr
Sicinski (Dana-Farber, Boston).
Author Contributions
Conceived and designed the experiments: SMF FAD. Performed the
experiments: SMF FAD. Analyzed the data: SMF SC FAD. Wrote the
manuscript: SMF FAD.
References
1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57–70.
2. Hennighausen L, Robinson GW (2001) Signaling pathways in mammary gland
development. Dev Cell 1: 467–475.
3. Massague J (2004) G1 cell-cycle control and cancer. Nature 432: 298–306.
4. Sherr CJ (1996) Cancer cell cycles. Science 274: 1672–1677.
5. Sherr CJ, Roberts JM (1995) Inhibitors of mammalian G1 cyclin-dependent
kinases. Genes Dev 9: 1149–1163.
6. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, et al. (1995)
Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:
552–557.
7. Brugarolas J, Moberg K, Boyd S, Taya Y, Jacks T, et al. (1999) Inhibition of
cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-
mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci USA 96:
1002–1007.
8. Florenes VA, Bhattacharya N, Bani MR, Ben-David Y, Kerbel RS, et al. (1996)
TGF-beta mediated G1 arrest in a human melanoma cell line lacking
p15INK4B: evidence for cooperation between p21Cip1/WAF1 and p27Kip1.
Oncogene 13: 2447–2457.
9. Iavarone A, Massague J (1997) Repression of the CDK activator Cdc25A and
cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15.
Nature 387: 417–422.
10. Missero C, di Cunto F, Kiyokawa H, Koff A, Dotto G (1996) The abscence of
p21 Cip1/WAF1 alters keratinocyte growth and differentiation and promotes
ras tumor progression. Genes Dev 10: 3065–3075.
11. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, et al. (1996) Mice
lacking p27(Kip1) display increased body size, multiple organ hyperplasia,
retinal dysplasia, and pituitary tumors. Cell 85: 707–720.
12. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, et al. (2001)
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.
Nature 413: 86–91.
13. Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A (2001) Loss of
p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 413:
83–86.
14. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, et al. (1996) A syndrome of
multiorgan hyperplasia with features of gigantism, tumorigenesis, and female
sterility in p27(Kip1)-deficient mice. Cell 85: 733–744.
15. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES,
et al. (1996) Enhanced growth of mice lacking the cyclin-dependent kinase
inhibitor function of p27(Kip1). Cell 85: 721–732.
16. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P (1995) Mice lacking
p21CIP1/WAF1 undergo normal development, but are defective in G1
checkpoint control. Cell 82: 675–684.
17. Krimpenfort P, Ijpenberg A, Song JY, van der Valk M, Nawijn M, et al. (2007)
p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature
448: 943–946.
18. Latres E, Malumbres M, Sotillo R, Martin J, Ortega S, et al. (2000) Limited
overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in
proliferation and tumorigenesis. Embo J 19: 3496–3506.
19. Robinson GW, Wagner KU, Hennighausen L (2001) Functional mammary
gland development and oncogene-induced tumor formation are not affected by
the absence of the retinoblastoma gene. Oncogene 20: 7115–7119.
20. Fernandez PL, Jares P, Rey MJ, Campo E, Cardesa A (1998) Cell cycle
regulators and their abnormalities in breast cancer. Mol Pathol 51: 305–309.
21. Bosco EE, Knudsen ES (2007) RB in breast cancer: at the crossroads of
tumorigenesis and treatment. Cell Cycle 6: 667–671.
22. Pietilainen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, et al. (1995)
Expression of retinoblastoma gene protein (Rb) in breast cancer as related to
established prognostic factors and survival. Eur J Cancer 31A: 329–333.
23. Borg A, Zhang QX, Alm P, Olsson H, Sellberg GE (1992) The retinoblastoma
gene in breast cancer: allele loss is not correlated with loss of gene protein
expression. Cancer Res 52: 2991–2994.
24. Nielsen NH, Emdin SO, Cajander J, Landberg G (1997) Deregulation of cyclin
E and D1 in breast cancer is associated with inactivation of the retinoblastoma
protein. Oncogene 14: 295–304.
25. Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81:
323–330.
26. Francis SM, Bergsied J, Isaac CE,Coschi CH, Martens AL, et al. (2009) A functional
connection between pRB and transforming growth factor beta in growth inhibition
and mammary gland development. Mol Cell Biol 29: 4455–4466.
27. Talluri S, Isaac CE, Ahmad M, Henley SA, Francis SM, et al. (2010) A G1
checkpoint mediated by the retinoblastoma protein that is dispensable in
terminal differentiation but essential for senescence. Mol Cell Biol 30: 948–960.
pRB-Dependent Negative Growth Response in Cancer
PLoS ONE | www.plosone.org 8 February 2011 | Volume 6 | Issue 2 | e1643428. Isaac CE, Francis SM, Martens AL, Julian LM, Seifried LA, et al. (2006) The
retinoblastoma protein regulates pericentric heterochromatin. Mol Cell Biol 26:
3659–3671.
29. Coschi CH, Martens AL, Ritchie K, Francis SM, Chakrabarti S, et al. (2010)
Mitotic chromosome condensation mediated by the retinoblastoma protein is
tumor-suppressive. Genes Dev 24: 1351–1363.
30. Page DL, Dupont WD, Rogers LW, Rados MS (1985) Atypical hyperplastic
lesions of the female breast. A long-term follow-up study. Cancer 55:
2698–2708.
31. Dupont WD, Page DL (1985) Risk factors for breast cancer in women with
proliferative breast disease. N Engl J Med 312: 146–151.
32. Ossovskaya VS, Mazo IA, Chernov MV, Chernova OB, Strezoska Z, et al.
(1996) Use of genetic suppressor elements to dissect distinct biological effects of
separate p53 domains. Proc Natl Acad Sci USA 93: 10309–10314.
33. Li B, Murphy KL, Laucirica R, Kittrell F, Medina D, et al. (1998) A transgenic
mouse model for mammary carcinogenesis. Oncogene 16: 997–1007.
34. Li B, Rosen JM, McMenamin-Balano J, Muller WJ, Perkins AS (1997) neu/
ERBB2 cooperates with p53-172H during mammary tumorigenesis in
transgenic mice. Mol Cell Biol 17: 3155–3163.
35. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, et al. (1992)
Expression of the neu protooncogene in the mammary epithelium of transgenic
mice induces metastatic disease. Proc Natl Acad Sci USA 89: 10578–10582.
36. Dankort DL, Wang Z, Blackmore V, Moran MF, Muller WJ (1997) Distinct
tyrosine autophosphorylation sites negatively and positively modulate neu-
mediated transformation. Mol Cell Biol 17: 5410–5425.
37. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J (2003) Transforming
growth factor beta signaling impairs Neu-induced mammary tumorigenesis
while promoting pulmonary metastasis. Proc Natl Acad Sci USA 100:
8430–8435.
38. Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, et al.
(2003) Increased malignancy of Neu-induced mammary tumors overexpressing
active transforming growth factor beta1. Mol Cell Biol 23: 8691–8703.
39. Siegel PM, Dankort DL, Hardy WR, Muller WJ (1994) Novel activating
mutations in the neu proto-oncogene involved in induction of mammary tumors.
Mol Cell Biol 14: 7068–7077.
40. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, et al.
(2000) The mammary pathology of genetically engineered mice: the consensus
report and recommendations from the Annapolis meeting. Oncogene 19:
968–988.
41. Ewan KB, Oketch-Rabah HA, Ravani SA, Shyamala G, Moses HL, et al. (2005)
Proliferation of estrogen receptor-alpha-positive mammary epithelial cells is
restrained by transforming growth factor-beta1 in adult mice. Am J Pathol 167:
409–417.
42. Hojilla CV, Kim I, Kassiri Z, Fata JE, Fang H, et al. (2007) Metalloproteinase
axes increase beta-catenin signaling in primary mouse mammary epithelial cells
lacking TIMP3. J Cell Sci 120: 1050–1060.
43. Pear WS, Nolan GP, Scott ML, Baltimore D (1993) Production of high-titre
helper-free retroviuses by transient transfection. Proc Natl Acad Sci USA 90:
8392–8396.
44. Dannenberg J-H, van Rossum A, Schuijff L, te Riele H (2000) Ablation of the
Retinoblastoma gene family deregulates G1 control causing immortalization and
increased cell turnover under growth-restricting conditions. Genes Dev 14:
3051–3064.
pRB-Dependent Negative Growth Response in Cancer
PLoS ONE | www.plosone.org 9 February 2011 | Volume 6 | Issue 2 | e16434